348 related articles for article (PubMed ID: 20502642)
1. Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome.
Moncaster JA; Pineda R; Moir RD; Lu S; Burton MA; Ghosh JG; Ericsson M; Soscia SJ; Mocofanescu A; Folkerth RD; Robb RM; Kuszak JR; Clark JI; Tanzi RE; Hunter DG; Goldstein LE
PLoS One; 2010 May; 5(5):e10659. PubMed ID: 20502642
[TBL] [Abstract][Full Text] [Related]
2. Alzheimer's disease amyloid-β pathology in the lens of the eye.
Moncaster JA; Moir RD; Burton MA; Chadwick O; Minaeva O; Alvarez VE; Ericsson M; Clark JI; McKee AC; Tanzi RE; Goldstein LE
Exp Eye Res; 2022 Aug; 221():108974. PubMed ID: 35202705
[TBL] [Abstract][Full Text] [Related]
3. In vivo quasi-elastic light scattering detects molecular changes in the lenses of adolescents with Down syndrome.
Sarangi S; Minaeva O; Ledoux DM; Parsons DS; Moncaster JA; Black CA; Hollander J; Tripodis Y; Clark JI; Hunter DG; Goldstein LE
Exp Eye Res; 2024 Apr; 241():109818. PubMed ID: 38422787
[TBL] [Abstract][Full Text] [Related]
4. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G
Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613
[TBL] [Abstract][Full Text] [Related]
5. Cytosolic beta-amyloid deposition and supranuclear cataracts in lenses from people with Alzheimer's disease.
Goldstein LE; Muffat JA; Cherny RA; Moir RD; Ericsson MH; Huang X; Mavros C; Coccia JA; Faget KY; Fitch KA; Masters CL; Tanzi RE; Chylack LT; Bush AI
Lancet; 2003 Apr; 361(9365):1258-65. PubMed ID: 12699953
[TBL] [Abstract][Full Text] [Related]
6. Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.
Doran E; Keator D; Head E; Phelan MJ; Kim R; Totoiu M; Barrio JR; Small GW; Potkin SG; Lott IT
J Alzheimers Dis; 2017; 56(2):459-470. PubMed ID: 27983553
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer's-like mouse models.
Kumar S; Lemere CA; Walter J
Acta Neuropathol Commun; 2020 Jul; 8(1):118. PubMed ID: 32727580
[TBL] [Abstract][Full Text] [Related]
8. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
Asai M; Kawakubo T; Mori R; Iwata N
Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
[TBL] [Abstract][Full Text] [Related]
9. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.
Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595
[TBL] [Abstract][Full Text] [Related]
10. Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21.
Mumford P; Tosh J; Anderle S; Gkanatsiou Wikberg E; Lau G; Noy S; Cleverley K; Saito T; Saido TC; Yu E; Brinkmalm G; Portelius E; Blennow K; Zetterberg H; Tybulewicz V; Fisher EMC; Wiseman FK
J Neurosci; 2022 Aug; 42(33):6453-6468. PubMed ID: 35835549
[TBL] [Abstract][Full Text] [Related]
11. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
[TBL] [Abstract][Full Text] [Related]
12. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.
Cataldo AM; Petanceska S; Terio NB; Peterhoff CM; Durham R; Mercken M; Mehta PD; Buxbaum J; Haroutunian V; Nixon RA
Neurobiol Aging; 2004; 25(10):1263-72. PubMed ID: 15465622
[TBL] [Abstract][Full Text] [Related]
13. Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
García-Cerro S; Rueda N; Vidal V; Lantigua S; Martínez-Cué C
Neurobiol Dis; 2017 Oct; 106():76-88. PubMed ID: 28647555
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
15. Microvascular changes in Down syndrome with Alzheimer's-type pathology: Insights into a potential vascular mechanism for Down syndrome and Alzheimer's disease.
Drachman DA; Smith TW; Alkamachi B; Kane K
Alzheimers Dement; 2017 Dec; 13(12):1389-1396. PubMed ID: 28627379
[TBL] [Abstract][Full Text] [Related]
16. Emergence of distinct and heterogeneous strains of amyloid beta with advanced Alzheimer's disease pathology in Down syndrome.
Maxwell AM; Yuan P; Rivera BM; Schaaf W; Mladinov M; Prasher VP; Robinson AC; DeGrado WF; Condello C
Acta Neuropathol Commun; 2021 Dec; 9(1):201. PubMed ID: 34961556
[TBL] [Abstract][Full Text] [Related]
17. In-vivo anterior segment OCT imaging provides unique insight into cerulean blue-dot opacities and cataracts in Down syndrome.
Little JA; Mahil AS; Richardson P; Woodhouse JM; Vinuela-Navarro V; Saunders KJ
Sci Rep; 2020 Jun; 10(1):10031. PubMed ID: 32572106
[TBL] [Abstract][Full Text] [Related]
18. Alzheimer's drugs, APPlication for Down syndrome?
Sokol DK; Lahiri DK
Ageing Res Rev; 2024 Apr; 96():102281. PubMed ID: 38513771
[TBL] [Abstract][Full Text] [Related]
19. Exploring Alzheimer molecular pathology in Down's syndrome cerebrospinal fluid.
Portelius E; Soininen H; Andreasson U; Zetterberg H; Persson R; Karlsson G; Blennow K; Herukka SK; Mattsson N
Neurodegener Dis; 2014; 14(2):98-106. PubMed ID: 24992945
[TBL] [Abstract][Full Text] [Related]
20. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
